Crinetics Pharmaceuticals announced that the European Medicines Agency (EMA) validated its Marketing Authorization Application (MAA) for paltusotine to treat...

Sensei Biotherapeutics announced preliminary positive results from the dose expansion portion of its Phase 1/2 trial of solnerstotug, a...

Bristol Myers Squibb (BMS) announced positive topline results from Phase 3 trials of Sotyktu (deucravacitinib) for psoriatic arthritis (PsA)....

Urteste S.A., a Polish company specializing in early cancer detection through urine analysis, plans to start clinical trials for...

Chemomab Therapeutics announced positive 48-week data from the open-label extension (OLE) of its Phase 2 SPRING trial for nebokitug...

In this interview, Francisco Salva, CEO of Azitra, shared insights into the company’s innovative approach to treating skin diseases....

Candel Therapeutics announced final survival data from a Phase 2a clinical trial of CAN-2409 in patients with advanced non-small...

Rani Therapeutics announced positive preclinical data for RT-114, an oral formulation of ProGen’s GLP-1/GLP-2 dual agonist, PG-102, for obesity...

Spherix’s recent study of 507 IgA nephropathy (IgAN) patients reveals a disconnect between treatment goals and real-world disease management,...

Sonnet BioTherapeutics announced positive safety data from an expansion cohort of its Phase 1 SB101 trial. The trial is...